Dr. Frank Longo, Stanford University professor of neurology and PharmatrophiX co-founder, joins ‘Squawk Box’ to discuss the company’s new Alzheimer’s drug LM11A-31
- Posted on Jul 28, 2026
How the new drug approaches treatment differently from existing Alzheimer’s therapies, and more.... Read More
Indiana University and PharmatrophiX Present Findings on Performance of Oral Therapeutic, LM11A-31, to Reduce Decline of Brain Functional-Network Connectivity in Alzheimer’s Disease
- Posted on Jul 13, 2026
New findings presented at featured research session (FRS) during the Alzheimer’s Association International Conference demonstrate statistically significant slowing of decline in brain network function with LM11A-31 vs placebo linked to cognitive domains and synaptic resilience MENLO PARK, California (July 13, 2026) – Indiana University and PharmatrophiX, a privately-held, clinical-stage biopharmaceutical company pioneering the development of ... Read More